These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Sibutramine for obesity. Med Lett Drugs Ther; 1998 Mar; 40(1022):32. PubMed ID: 9529518 [No Abstract] [Full Text] [Related]
5. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Perrio MJ; Wilton LV; Shakir SA Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762 [TBL] [Abstract][Full Text] [Related]
6. Sibutramine: an Australian analysis of reported adverse effects. Prescrire Int; 2007 Jun; 16(89):114. PubMed ID: 17590911 [No Abstract] [Full Text] [Related]
7. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? von Haehling S; Lainscak M; Anker SD Eur Heart J; 2007 Dec; 28(23):2830-1. PubMed ID: 17984134 [No Abstract] [Full Text] [Related]
8. The effect of sibutramine therapy on occurrence of depression symptoms among obese patients. Slovacek L; Pavlik V; Slovackova B Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):e43-4. PubMed ID: 18676135 [No Abstract] [Full Text] [Related]
9. Sibutramine and blood pressure: a therapeutic dilemma. Bray GA J Hum Hypertens; 2002 Jan; 16(1):1-3. PubMed ID: 11840223 [No Abstract] [Full Text] [Related]
10. Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome. Georgopoulos NA; Katsikis I; Florakis D; Panidis D; Kandarakis ED Fertil Steril; 2009 Jun; 91(6):e1. PubMed ID: 19362719 [No Abstract] [Full Text] [Related]
11. European Medicines Agency withdrawal for sibutramine. Galhardo J; Davis N; Matthai S; Shield JP Arch Dis Child; 2010 Oct; 95(10):856. PubMed ID: 20573736 [No Abstract] [Full Text] [Related]
12. Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up. De Santis M; Straface G; Cavaliere AF; Carducci B; Caruso A Drug Saf; 2006; 29(3):255-9. PubMed ID: 16524324 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of obesity in practice - more necessary than ever]. Wirth A Dtsch Med Wochenschr; 2002 Mar; 127(12):605. PubMed ID: 11907861 [No Abstract] [Full Text] [Related]
14. Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme. Hill GR; Ashton J; Harrison-Woolrych M Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1217-26. PubMed ID: 17661435 [TBL] [Abstract][Full Text] [Related]
15. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Finer N; Ryan DH; Renz CL; Hewkin AC Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525 [TBL] [Abstract][Full Text] [Related]
16. Sibutramine use in pregnancy: report of two cases. Kadioglu M; Ulku C; Yaris F; Kesim M; Kalyoncu NI; Yaris E Birth Defects Res A Clin Mol Teratol; 2004 Aug; 70(8):545-6. PubMed ID: 15329834 [TBL] [Abstract][Full Text] [Related]
17. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. Wooltorton E CMAJ; 2002 May; 166(10):1307-8. PubMed ID: 12041851 [No Abstract] [Full Text] [Related]
18. [Patients with type III obesity given sibutramine 15 mg/day lose weight in amounts proportional to those in types I and II, but waist circumferences does not decrease proportionally]. López-Alvarenga JC; Vargas JA; Schneider-Ehrenberg OP; Comuzzie AG; González J; Martínez JL Gac Med Mex; 2007; 143(2):109-14. PubMed ID: 17585697 [TBL] [Abstract][Full Text] [Related]
19. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258 [TBL] [Abstract][Full Text] [Related]
20. Drug therapy for obesity: clarifications. Seaton TB J Am Pharm Assoc (Wash); 1997; NS37(4):374. PubMed ID: 9519642 [No Abstract] [Full Text] [Related] [Next] [New Search]